Piratvisuth, Teerha

Publishing since 1994 (Senior)

Has published 27 publications in 17 years

Number of publications published per year by Piratvisuth, Teerha. (Source : PubMed)

Distribution of publications types for Piratvisuth, Teerha. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon.  Liver Int.  2010  
•  Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.  Hepatology international  2010;4;1  
•  Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.  Gastroenterology  2009;137;6  
•  You J, Zhuang L, Zhang YF, Chen HY, Sriplung H, Geater A, Chongsuvivatwong V, Piratvisuth T, McNeil E, Yu L, Tang BZ, Huang JH. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load.  World J. Gastroenterol.  2009;15;27  
•  Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a.  Gastroenterology  2009;136;7  
•  Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.  Hepatology  2009;49;4  
•  Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.  Hepatology international  2008;2;3  
•  Piratvisuth T. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B.  Hepatology international  2008;2;2  
•  Marcellin P, Lau GK, Zeuzem S, Heathcote EJ, Pockros PJ, Reddy KR, Piratvisuth T, Farci P, Chow WC, Jia JD, Paik W, Wintfeld N, Pluck N. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a.  Liver Int.  2008;28;4  
•  Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P, Popescu M. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.  Hepatology international  2008;2;1  

[ See timeline ] [ See all publications ]